178 related articles for article (PubMed ID: 3873905)
1. In vitro susceptibilities and beta-lactamase production of 53 clinical isolates of Branhamella catarrhalis.
Alvarez S; Jones M; Holtsclaw-Berk S; Guarderas J; Berk SL
Antimicrob Agents Chemother; 1985 Apr; 27(4):646-7. PubMed ID: 3873905
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic susceptibility of beta-lactamase-producing strains of Branhamella (Neisseria) catarrhalis.
Doern GV; Siebers KG; Hallick LM; Morse SA
Antimicrob Agents Chemother; 1980 Jan; 17(1):24-9. PubMed ID: 6766292
[TBL] [Abstract][Full Text] [Related]
3. The incidence and antibiotic susceptibility of Branhamella catarrhalis in respiratory infections.
Calder MA; Croughan MJ; McLeod DT; Ahmad F
Drugs; 1986; 31 Suppl 3():11-6. PubMed ID: 3488189
[TBL] [Abstract][Full Text] [Related]
4. Clinical and bacteriological evaluation of Branhamella catarrhalis in respiratory infections.
Saito A; Yamaguchi K; Shigeno Y; Kohno S; Shigeno H; Kusano N; Dotsu Y; Hara K
Drugs; 1986; 31 Suppl 3():87-92. PubMed ID: 3488201
[TBL] [Abstract][Full Text] [Related]
5. Branhamella catarrhalis: antibiotic susceptibility and beta-lactamase production.
Brorson JE; Martinell J; Wilske H
J Antimicrob Chemother; 1981 Feb; 7(2):208-9. PubMed ID: 6971288
[No Abstract] [Full Text] [Related]
6. In vitro activity of amoxicillin plus clavulanic acid against Haemophilus influenzae and Branhamella catarrhalis.
Liljequist BO; Gezelius L
Eur J Clin Microbiol; 1986 Dec; 5(6):615-21. PubMed ID: 3492374
[TBL] [Abstract][Full Text] [Related]
7. [Respiratory tract infection with Branhamella catarrhalis].
Matsumoto K; Nagatake T; Uzuka Y; Rikitomi N; Noguchi Y
Nihon Naika Gakkai Zasshi; 1982 Dec; 71(12):1696-702. PubMed ID: 6984859
[No Abstract] [Full Text] [Related]
8. [Serotype distribution and drug resistance of
Tian HL; Shi W; Zhou HF; Yuan L; Yao KH; Rexiati D; Xu AM
Zhonghua Er Ke Za Zhi; 2018 Apr; 56(4):279-283. PubMed ID: 29614568
[No Abstract] [Full Text] [Related]
9. Detection, distribution and inhibition of Branhamella catarrhalis beta-lactamases.
Philippon A; Riou JY; Guibourdenche M; Sotolongo F
Drugs; 1986; 31 Suppl 3():64-9. PubMed ID: 3015547
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial susceptibility and beta-lactamase characterization of Branhamella catarrhalis isolates from 1983/1984 and 1988.
Christensen JJ; Keiding J; Bruun B
APMIS; 1990 Nov; 98(11):1039-44. PubMed ID: 2123390
[TBL] [Abstract][Full Text] [Related]
11. Branhamella catarrhalis: an unappreciated pulmonary pathogen.
Roth RM; Gleckman RA; Hibert DM
Am Fam Physician; 1984 Oct; 30(4):169-73. PubMed ID: 6333806
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibilities of isolates from patients with Branhamella catarrhalis pneumonia compared with those of colonizing strains.
Sweeney KG; Verghese A; Needham CA
Antimicrob Agents Chemother; 1985 Apr; 27(4):499-502. PubMed ID: 3873899
[TBL] [Abstract][Full Text] [Related]
13. β-Lactamase production and antibiotic susceptibility pattern of Moraxella catarrhalis isolates collected from two county hospitals in China.
Shi W; Wen D; Chen C; Yuan L; Gao W; Tang P; Cheng X; Yao K
BMC Microbiol; 2018 Jul; 18(1):77. PubMed ID: 30029595
[TBL] [Abstract][Full Text] [Related]
14. Upper respiratory tract infections. Ecological and therapeutic aspects of beta-lactamase production with special reference to Branhamella catarrhalis.
Eliasson I; Kamme C
Drugs; 1986; 31 Suppl 3():116-21. PubMed ID: 3488190
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of respiratory infection caused by Branhamella catarrhalis with special reference to beta-lactamase producing strains.
Nagatake T
Tohoku J Exp Med; 1985 Sep; 147(1):1-13. PubMed ID: 3000026
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of BRL 17421 against Haemophilus influenzae, Neisseria gonorrhoeae, and Branhamella catarrhalis.
Piot P; Van Dyck E
Antimicrob Agents Chemother; 1982 Jan; 21(1):166-7. PubMed ID: 6805422
[TBL] [Abstract][Full Text] [Related]
17. Antibacterial activity of nine oral antibiotics against Streptococcus pneumoniae, Haemophilus influenzae and Branhamella catarrhalis.
Renkonen OV
Scand J Infect Dis Suppl; 1983; 39():106-8. PubMed ID: 6606222
[TBL] [Abstract][Full Text] [Related]
18. Moraxella catarrhalis: clinical significance, antimicrobial susceptibility and BRO beta-lactamases.
McGregor K; Chang BJ; Mee BJ; Riley TV
Eur J Clin Microbiol Infect Dis; 1998 Apr; 17(4):219-34. PubMed ID: 9707304
[TBL] [Abstract][Full Text] [Related]
19. Disk diffusion susceptibility of Branhamella catarrhalis and relationship of beta-lactam zone size to beta-lactamase production.
Luman I; Wilson RW; Wallace RJ; Nash DR
Antimicrob Agents Chemother; 1986 Nov; 30(5):774-6. PubMed ID: 3492178
[TBL] [Abstract][Full Text] [Related]
20. Amoxycillin-clavulanic acid combination in bronchopulmonary infection due to beta-lactamase-producing Branhamella catarrhalis. Preliminary report.
Thornley PE; Aitken JM; Nichol GM; Slevin NJ
Drugs; 1986; 31 Suppl 3():113-4. PubMed ID: 3525087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
